Analysts at Morgan Stanley initiated coverage on shares of Shockwave Medical (NASDAQ:SWAV) in a research note issued on Monday, April 1st, Marketbeat Ratings reports. The brokerage set an “equal weight” rating and a $32.00 price target on the stock. Morgan Stanley’s target price would indicate a potential downside of 7.25% from the company’s previous close.
SWAV stock traded up $3.26 during trading on Monday, reaching $34.50. The company had a trading volume of 260,900 shares, compared to its average volume of 267,576. Shockwave Medical has a 52 week low of $24.58 and a 52 week high of $43.39.
In related news, insider James E. Flynn purchased 30,000 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The stock was bought at an average cost of $17.00 per share, with a total value of $510,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Shockwave Medical Company Profile
ShockWave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease.
Featured Story: Should You Consider an Index Fund?
Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.